(4-溴-3-氯苯基)甲醇 | 120077-68-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-溴-3-氯苯基)甲醇
• 英文名称: (4-bromo-3-chlorophenyl)methanol
• CAS: 120077-68-1
• 化学式: C₇H₆BrClO
• mdl: MFCD08059111
• 分子量: 221.481
• InChiKey: QXKNNVRGECWRKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P233,P260,P261,P264,P271,P280,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  (4-溴-3-氯苯基)甲醇 在 manganese(IV) oxide 、 三乙酰氧基硼氢化钠 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 141.25h， 生成 1-(2,2'-dichlorobiphenyl-4-yl)-N-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)-N-methylmethanamine
  参考文献：
  名称：

  Chemical Subtleties in Small-Molecule Modulation of Peptide Receptor Function: The Case of CXCR3 Biaryl-Type Ligands

  摘要：

  The G protein-coupled chemokine receptor CXCR3 plays a role in numerous inflammatory events. The endogenous ligands for the chemokine receptors are peptides, but in this study we disclose small-molecule ligands that are able to activate CXCR3. A class of biaryl-type compounds that is assembled by convenient synthetic routes is described as a new class of CXCR3 agonists. Intriguingly, structure-activity relationship and structure-function relationship studies reveal that subtle chemical modifications on the outer aryl ring (e.g., either the size or position of a halogen atom) result in a full spectrum of agonist efficacies on CXCR3. Quantum mechanics calculations and nuclear Overhauser effect spectroscopy NMR studies suggest that the biaryl dihedral angle and the electronic nature of ortho-substituents play an important role in determining agonist efficacies. Compounds 38 (VUF11222) and 39 (VUF11418) are the first reported nonpeptidomimetic agonists on CXCR3, rendering them highly useful chemical tools for detailed assessment of CXCR3 activation as well as for studying downstream CXCR3 signaling.

  DOI：

  10.1021/jm301240t
• 作为产物：
  描述：

  4-溴-3-氯苯甲酸 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 生成 (4-溴-3-氯苯基)甲醇
  参考文献：
  名称：

  亲水，有力和选择性7取代的2-氨基喹啉作为改进的人类神经元一氧化氮合酶抑制剂。

  摘要：

  神经元型一氧化氮合酶（nNOS）是开发抗神经退行性药物的目标。大多数的nNOS抑制剂模仿升-精氨酸，生物利用度差。2-氨基喹啉显示出作为生物可利用的nNOS抑制剂的前景，但遭受人类nNOS抑制作用低，相对于人类eNOS的选择性低以及与其他CNS靶标的显着结合。我们的目标是通过（a）截短原始支架或（b）引入亲水基团以中断亲脂性，混杂的药效团并促进与人nNOS特异性His342的相互作用来提高人nNOS的效力和选择性，并减少脱靶结合。我们合成了截短的和极性的2-氨基喹啉衍生物，并针对重组NOS酶对其进行了测定。尽管苯胺和吡啶衍生物与His342相互作用，但苄腈赋予大鼠和人nNOS最佳的抑制作用。在氰基附近引入疏水性取代基和氨基喹啉甲基化都大大改善了同工型的选择性。最重要的是，这些修饰保留了Caco-2的通透性并减少了脱靶CNS的结合。

  DOI：

  10.1021/acs.jmedchem.7b00835

文献信息

• [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078331A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
• [EN] 4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS<br/>[FR] INHIBITEURS DE DGAT1 À BASE DE 4-AMINO-7,8-DIHYDROPYRIMIDO[5,4,F][1,4]OXAZÉPIN-5(6H)-ONE
  申请人：ASTRAZENECA AB

  公开号：WO2011121350A1

  公开（公告）日：2011-10-06

  DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity wherein, R1, R2, R3, R4, X2, q, Y1, Y2, n, Q and Z are as defined in the description.

  DGAT-1抑制剂化合物公式(I)，药用可接受的盐和前药，以及药物组合物、制造它们的方法以及它们在治疗例如糖尿病和肥胖症中的用途，其中，R1、R2、R3、R4、X2、q、Y1、Y2、n、Q和Z在描述中定义。
• Heterocyclic pesticidal compounds
  申请人：The Wellcome Foundation

  公开号：US05502073A1

  公开（公告）日：1996-03-26

  Compounds of the formula (I) ##STR1## which contain between 10 and 27 carbon atoms, and wherein m and n are independently selected from 0, 1 and 2; R.sup.2a is hydrogen, methyl, or ethyl; R.sup.2b is acetylene or contains between 3 and 18 carbon atoms and is a group R.sup.7, wherein R.sup.7 is a C.sub.1-13 non-aromatic hydrocarbyl group, optionally substituted by a cyano or C.sub.1-4 carbalkoxy group and/or by one or two hydroxy groups and/or by one to five halo atoms which are the same or different and/or by one to three groups R.sup.8 which are the same or different and each contain one to four hetero atoms, which are the same or different and are chosen from oxygen, sulphur, nitrogen and silicon, 1 to 10 carbon atoms and optionally 1 to 6 fluoro or chloro atoms or R.sup.2b is a 6-membered aromatic ring substituted by cyano and/or by one to three groups R.sup.8 and/or by a group --C.tbd.CH, --C.tbd.C-R.sup.7 or C.tbd.C-halo and/or by one to five halo atoms and/or by one to three C.sub.1-4 haloalkyl groups wherein R.sup.7 and R.sup.8 are as hereinbefore defined; R.sup.4 and R.sup.6 are the same or different and are chosen from hydrogen, methyl, trifluoromethyl or cyano; and R.sup.5 is hydrogen or methyl provided that R.sup.2b is not propyl or butyl are described which have pesticidal activity, particularly against arthropod pests. Pesticidal formulations containing the compounds of the formula (I), their use in the control of pests and method for their preparation are also disclosed.

  化学式（I）##STR1##中含有10至27个碳原子，其中m和n分别选自0、1和2；R.sup.2a为氢、甲基或乙基；R.sup.2b为乙炔或含有3至18个碳原子且为基团R.sup.7，其中R.sup.7为C.sub.1-13非芳香烃基团，可选择地被氰基或C.sub.1-4羰基烷氧基团取代和/或被一个或两个羟基取代和/或被一个到五个相同或不同的卤原子取代和/或被一个到三个相同或不同的基团R.sup.8取代，每个基团R.sup.8含有一个到四个相同或不同的杂原子，这些杂原子选自氧、硫、氮和硅，1至10个碳原子和可选择地1至6个氟或氯原子，或R.sup.2b为被氰基取代的6元芳环和/或被一个到三个基团R.sup.8取代和/或为基团--C.tbd.CH、--C.tbd.C-R.sup.7或C.tbd.C-卤基取代和/或被一个到五个卤原子取代和/或被一个到三个C.sub.1-4卤代烷基团取代，其中R.sup.7和R.sup.8如前所定义；R.sup.4和R.sup.6相同或不同，选自氢、甲基、三氟甲基或氰基；R.sup.5为氢或甲基，前提是R.sup.2b不是丙基或丁基，描述了具有杀虫活性的化合物，特别是对节肢动物害虫。还公开了含有化合物（I）的杀虫配方，其在害虫控制中的使用以及其制备方法。
• Modulators of methyl modifying enzymes, compositions and uses thereof
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：US09206128B2

  公开（公告）日：2015-12-08

  Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

  这里提供了调节甲基修饰酶的药剂、组合物及其用途。
• [EN] ESTROGEN RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE RÉCEPTEURS D'OESTROGÈNES ET LEURS UTILISATIONS
  申请人：SERAGON PHARMACEUTICALS INC

  公开号：WO2013142266A1

  公开（公告）日：2013-09-26

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括本文描述的化合物在内的药物组合物和药物，以及使用这些雌激素受体调节剂的方法，单独或与其他化合物结合，用于治疗与雌激素受体介导或依赖的疾病或症状。